BioSpace News Archive

Deals

Genmab Raises $506 Million in IPO

Genmab A/S, located in Copenhagen, Denmark, raised $506 million with its initial public offering (IPO). The company trades on the Nasdaq under the ticker symbol GMAB.

July 18, 2019
·
2 min read
·
Mark Terry
Business

Mallinckrodt and Silence Therapeutics Forge RNAi Deal Worth up to $2 Billion

The companies will develop therapies that target the complement cascade, a group of proteins known to play a role in autoimmune diseases.

July 18, 2019
·
3 min read
·
Alex Keown
Business

Kronos Bio Snags $105 Million to Support Development of its Small Molecule Microarray Platform

Since its launch, Kronos has demonstrated SMM’s potential to identify compounds that bind to target proteins directly or interfere at nanomolar potency with protein activity.

July 18, 2019
·
2 min read
·
Alex Keown
Business

Bayer, Bristol-Myers Squibb and Ono Pharma Team on Colorectal Cancer

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Co. have teamed up to study the most common type of metastatic colorectal cancer (mCRC).

July 18, 2019
·
2 min read
·
Mark Terry
Business

Precision BioSciences Opens First In-House cGMP Manufacturing Facility Dedicated to Genome-Edited Allogeneic CAR T Cell Therapy in the United States

Research Triangle Park Facility to Manufacture Precision’s Pipeline of Off-the-Shelf CAR T Product Candidates to Support Clinical Trials

July 18, 2019
·
5 min read
Biotech Bay

Elon Musk Presentation On Brain-Machine Interface Features XVIVO Scientific Animation

On July 16, 2019, tech entrepreneur Elon Musk presented his vision for high-bandwidth brain-machine interfaces to connect humans and computers with help from XVIVO Scientific Animation, a leading scientific and medical animation studio based in Connecticut

July 18, 2019
·
1 min read
Drug Development

Discovery shows how difficult-to-treat prostate cancer evades immune system

Study reports pre-clinical development of novel treatment and potential for combination use with immunotherapy drugs

July 18, 2019
·
3 min read
Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt

In May, the company sold off assets worth $5.7 billion and now, the company is looking to sell more.

July 18, 2019
·
2 min read
·
Alex Keown
Biotech Bay

Research Roundup: The Link Between Sugary Drinks and Cancer and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

July 18, 2019
·
4 min read
·
Mark Terry
BioCapital

Roche and Novo Nordisk Top Clinical Trial Transparency Survey

In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.

July 18, 2019
·
3 min read
·
Alex Keown